• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconNovo Nordisk

Novo Nordisk

Page 7 of 9
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity.
Retail
Novo Nordisk’s Wegovy and Ozempic boom saved Denmark’s GDP from a no-growth 2023—and will help double its expected growth this year, country’s largest bank says
By Niclas Rolander and BloombergMarch 5, 2024
Stock traders from various companies work in five circular and one semi-circular trading floor at the Frankfurt Stock Exchange.
Finance
Meet Europe’s answer to the ‘Magnificent 7’—the high-flying ‘Granolas’ that Goldman Sachs is betting will prosper in the continent’s flatlining economy
By Ryan HoggMarch 3, 2024
WHO
Health
A billion people worldwide are obese and Ozempic and other weight-loss drugs aren’t a solution, WHO says
By Naomi Kresge, Angela Feliciano and BloombergMarch 1, 2024
BOXES OF WEGOVY DRUGS
Lifestyle
Novo Nordisk faces competition close to home as Danish rival Zealand Pharma’s shares jump 35% on ‘groundbreaking’ weight-loss drug trial results
By Prarthana PrakashFebruary 27, 2024
Minnesotans can buy insulin for just $35 a month over the next 5 years under a state settlement with Eli Lilly
Health
Minnesotans can buy insulin for just $35 a month over the next 5 years under a state settlement with Eli Lilly
By Steve Karnowski and The Associated PressFebruary 8, 2024
Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
Retail
Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
By Ryan HoggFebruary 8, 2024
European stocks are giving off a ’90s vibe, Morgan Stanley says, and it could set them on a path to 16% returns in 2024
Finance
European stocks are giving off a ’90s vibe, Morgan Stanley says, and it could set them on a path to 16% returns in 2024
By Ryan HoggFebruary 6, 2024
Lars Fruergaard Jorgensen holding flashcards and talking
Retail
Novo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out of pocket for them
By Prarthana PrakashFebruary 5, 2024
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
Retail
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By Ryan HoggJanuary 31, 2024
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
Health
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
By Simone Foxman, Madison Muller and BloombergJanuary 27, 2024
Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
Health
Ozempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
By Ellie Harmsworth and BloombergDecember 24, 2023
Ozempic manufactured by Novo Nordisk packaging on December 7, 2023.
Health
Novo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival
By Christian Wienberg and BloombergDecember 13, 2023
Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
Finance
Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
By Paula Doenecke and BloombergDecember 4, 2023
Weight loss drugs are all the rage.
Health
Pfizer rocked by failure of weight-loss pill set to compete with lucrative rivals Ozempic and Mounjaro
By Madison Muller and BloombergDecember 1, 2023
Lars Fruergaard Jorgensen holding a microphone in one hand and paper flashcards in the other hand
Health
Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs
By Prarthana PrakashNovember 27, 2023
1...
  • 5
  • 6
  • 7
  • 8
  • 9
9
Most Popular
Economy
How Scott Bessent used financial engineering to finance the $2 trillion deficit while leaving it untouched—and created a $1.45 trillion shortfallplaceholder alt text
By Eva RoytburgAugust 8, 2026
Real Estate
Meet the 33-year-old CEO betting on boomers chasing their grandkids—and millennials selling their first houseplaceholder alt text
By Nick LichtenbergAugust 8, 2026
Real Estate
The tables have turned: Florida and Texas are the biggest losers in the housing market as Ohio emerges a surprise winnerplaceholder alt text
By Sydney LakeAugust 8, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.